Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management
I'm PortAI, I can summarize articles.
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Clene Inc., with a $20 price target, citing advancements in CNM-Au8 for neurological disorders and strategic financial management. Clene's stock has risen 220.30% in six months. Roth MKM also maintained a Buy rating with a $30 target. CNM-Au8's Orphan Drug Designation could expedite FDA approval by late 2026, making Clene a compelling buy opportunity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments